biei resources

SUPPORTING INFECTIOUS DISEASE RESEARCH

Escherichia coli – Staphylococcus aureus Shuttle Vector pKK22, Recombinant in Escherichia coli

Catalog No. NR-50348

For research use only. Not for use in humans.

Contributor:

Jeffrey L. Bose, Assistant Professor, Departments of Microbiology, Molecular Genetics and Immunology, University of Kansas Medical Center, Kansas City, Kansas, USA and Eric V. Stabb, Associate Head, Department of Microbiology, Franklin College of Arts and Sciences, University of Georgia, Athens, Georgia, USA

Manufacturer:

BEI Resources

Product Description:

NR-50348 is a preserved culture of Escherichia coli (E. coli), strain DH5αλpir containing the E. coli – staphylococcal shuttle vector pKK22. Vector pKK22 contains the E. coli R6Ky origin of replication and is for use in E. coli and Staphylococcus aureus (S. aureus) USA300 strains that contain LAC-p01, rendering them isogenic.^{1,2} Vector pKK22 contains a single trimethoprim resistance cassette that is functional in both E. coli and S. aureus.¹ The complete pKK22 nucleotide sequence has been sequenced (GenBank: KX085042) and the vector map of pKK22 is available in Appendix I.

pKK22 was deposited in conjunction with pKK30 and E. coli strains DH5αλpir and GM2163λpir (Table 1). pKK22 and pKK30 were created to maintain stability in E. coli and Staphylococcus species without antibiotic selection during in vitro and in vivo experiments. The E. coli R6Ky origin of replication of both vectors requires pir+ for replication which is provided in either DH5αλpir or GM2163λpir E. coli strains.³

Table 1: E. coli – Staphylococcus Vectors and Hosts

Catalog Number	Vector or Host	Comments
NR-50348	pKK22	For use in <i>E. coli</i> , strains DH5αλpir or GM2163λpir or <i>S. aureus</i> USA300 strains containing LAC-p01 ²
NR-50349	pKK30	pKK30 is a variant of pKK22, for use in <i>E. coli</i> , strains DH5αλpir or GM2163λpir or <i>Staphylococcus</i> species not containing LAC-p01 ²
NR-50350	<i>E. coli</i> , Strain DH5αλpir	Host strain containing the <i>pir</i> genes for performing genetic manipulations prior to transfer into <i>Staphylococcus</i> ³
NR-50351	<i>E. coli</i> , Strain GM2163λpir	Host strain containing the <i>pir</i> genes for performing genetic manipulations. This strain is also a Dam and Dcm methylase mutant for transfer of plasmids into <i>Staphylococcus</i> isolates that do not accept <i>E. coli</i> DNA easily. ³

Each vial of NR-50348 contains approximately 0.5 mL of Escherichia coli - Staphylococcus aureus Shuttle Vector pKK22, Recombinant in Escherichia coli in Tryptic Soy broth containing 10 µg/mL trimethoprim supplemented with 10% glycerol.

Packaging/Storage:

Material Provided:

NR-50348 was packaged aseptically in cryovials. The product is provided frozen and should be stored at -60°C or colder immediately upon arrival. For long-term storage, the vapor phase of a liquid nitrogen freezer is recommended. Freezethaw cycles should be avoided.

Growth Conditions:

Media:

- Tryptic Soy broth or equivalent with or without 10 µg/mL trimethoprim
- Tryptic Soy agar or Nutrient agar or Tryptic Soy agar with 5% defibrinated sheep blood or equivalent; with or without 10 µg/mL trimethoprim

Incubation:

Temperature: 37°C

Atmosphere: Aerobic

Propagation:

- Keep vial frozen until ready for use, then thaw, 1.
- 2. Transfer the entire thawed aliquot into a single tube of broth.
- 3. Use several drops of the suspension to inoculate an agar slant and/or plate.
- 4. Incubate the tube, slant and/or plate at 37°C for 1 day.

Citation:

Acknowledgment for publications should read "The following reagent was contributed by Dr. J. L. Bose for distribution by BEI Resources, NIAID, NIH: Escherichia coli -Staphylococcus aureus Shuttle Vector pKK22, Recombinant in Escherichia coli, NR-50348."

Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services. Public Health Service. Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories (BMBL). Current Edition. Washington, DC: U.S. Government Printing Office.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC[®] nor the U.S. Government makes any

E-mail: contact@beiresources.org Tel: 800-359-7370 Fax: 703-365-2898 **DICIÍ** RESOURCES

SUPPORTING INFECTIOUS DISEASE RESEARCH

warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC[®] nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC[®] and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC[®], their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:

- 1. Bose, J. L., Personal Communication.
- Krute, C. N., et al. "Generation of a Stable Plasmid for *In* Vitro and *In Vivo* Studies of Staphylococcus Species." <u>Appl. Environ. Microbiol.</u> 82 (2016): 6859-6869. PubMed: 27637878.
- Dunn, A. K., M. O. Martin and E. V. Stabb. "Characterization of pES213, A Small Mobilizable Plasmid from *Vibrio fischeri.*" <u>Plasmid</u> 54 (2005): 114-134. PubMed: 16122560.

ATCC[®] is a trademark of the American Type Culture Collection.



DICIÍ RESOURCES

SUPPORTING INFECTIOUS DISEASE RESEARCH

APPENDIX I: VECTOR pKK22 MAP



Notes:

- pKK22 is designed to be used in USA300 strains of S. aureus containing LAC-p01 (pUSA01)
- Entire plasmid sequence can be found in GenBank Accession KX085042
- tmpR denotes trimethoprim resistance in both E. coli and Staphylococcus species
- Clal site is methylation blocked and sits between the promoter and dfrA gene
- The R6Kγ origin of replication requires pir+ strains of E. coli to replicate